AGTC to Present at Upcoming Conferences
September 20 2017 - 7:00AM
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a
biotechnology company conducting human clinical trials of
adeno-associated virus (AAV)-based gene therapies for the treatment
of rare and debilitating diseases, today announced management will
be participating in the following conferences:
- Boston Biotech Conferences Cell & Gene Therapy CEO
— Boston (September 25, 2017)AGTC Chief Business Officer
Stephen Potter will moderate a panel discussion titled “Maximizing
Tech Transfer for Therapeutic Development” at 11:00am ET.
- FierceBiotech Drug Development Forum — Boston
(September 27, 2017)AGTC President & CEO Sue Washer
will lead a presentation titled “Build Internal Multi-Division
Teams for Successful Product Advancement” at 11:15am ET.
AGTC's lead product candidates are designed to
treat inherited orphan diseases of the eye, caused by mutations in
single genes that significantly affect visual function and
currently lack effective medical treatments.
AGTC's pipeline includes ophthalmology programs
in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa
(XLRP), achromatopsia caused by mutations in the CNGB3 and CNGA3
genes, wet age-related macular degeneration and an optogenetics
program.
About AGTC
AGTC is a clinical-stage biotechnology company that uses a
proprietary gene therapy platform to develop transformational
genetic therapies for patients suffering from rare and debilitating
diseases. Its initial focus is in the field of ophthalmology,
where it has active clinical trials in X-linked retinoschisis
(XLRS), X-linked retinitis pigmentosa (XLRP), and achromatopsia
(ACHM CNGB3 & ACHM CNGA3). In addition to its clinical
trials, AGTC has preclinical programs in optogenetics,
adrenoleukodystrophy (ALD), which is a disease of the central
nervous system (CNS), and otology. The clinical-stage XLRS and XLRP
programs, the discovery program in ALD and two additional
ophthalmology programs are being developed in collaboration with
Biogen. In addition to its product pipeline, AGTC has a significant
intellectual property portfolio and extensive expertise in the
design of gene therapy products including capsids, promoters and
expression cassettes, as well as expertise in the formulation,
manufacture and physical delivery of gene therapy
products.
IR/PR CONTACTS:
David Carey (IR) or Tom Vickery (PR)Lazar Partners Ltd.T: (212)
867-1768 or (646) 871-8482dcarey@lazarpartners.com or
tvickery@lazarpartners.com
CORPORATE CONTACTS:
Bill SullivanChief Financial OfficerApplied Genetic Technologies
CorporationT: (617) 843-5728 bsullivan@agtc.com
Stephen PotterChief Business OfficerApplied Genetic Technologies
CorporationT: (617) 413-2754spotter@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2023 to Apr 2024